This company has been marked as potentially delisted and may not be actively trading. NASDAQ:ACLX Arcellx (ACLX) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsEarningsFDA EventsHeadlinesInsider TradesOwnershipShort InterestTrendsBuy This Stock About Arcellx Stock (NASDAQ:ACLX) Get Arcellx alerts:Sign Up Key Stats Today's Range$114.99▼$115.1350-Day Range$113.76▼$115.1052-Week Range$47.86▼$115.13Volume14.67 million shsAverage Volume1.50 million shsMarket Capitalization$6.73 billionP/E RatioN/ADividend YieldN/APrice Target$111.87Consensus RatingHold Company Overview Arcellx, Inc. (NASDAQ: ACLX) is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of next-generation cell therapies for oncology and autoimmune diseases. The company’s proprietary ARC-SparX™ platform is designed to enable precise control over cell-surface receptor activation and to improve the safety, efficacy and durability of adoptive cell therapies. Leveraging this technology, Arcellx engineers immune cells with modular antigen-binding domains that can be exchanged to target a variety of disease-associated markers. The company’s pipeline comprises multiple wholly owned programs in hematologic malignancies and solid tumors at various stages of preclinical and clinical development. Arcellx is advancing lead clinical candidates for relapsed or refractory blood cancers, while exploring applications in solid tumors and autoimmune indications. Manufacturing operations are conducted at the company’s proprietary facility in Malvern, Pennsylvania, with additional process development and scale-up capabilities in the greater Philadelphia region. Founded in 2018, Arcellx has established collaborations with academic centers and contract research organizations across North America and Europe to support its clinical trial activities. The company is led by an experienced management team with deep expertise in cell therapy research, clinical development and biomanufacturing. Arcellx’s leadership is committed to translating its engineered cell technology into novel treatments that can overcome the limitations of current approaches and address significant unmet medical needs.AI Generated. May Contain Errors. Read More Receive ACLX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Arcellx and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ACLX Stock News HeadlinesGilead Sciences Completes Acquisition of Arcellx Ahead of Potential Commercial Launch of Anito-celApril 28, 2026 | businesswire.comGilead extends Arcellx tender offer againApril 17, 2026 | seekingalpha.comThe REAL Reason Trump is Invading IranFor a moment… Forget about Trump’s ties to Israel. Forget about reports of Iran’s nuclear program. Because my research has led me to believe we’re risking World War 3 with Iran for a completely different reason.July 20 at 1:00 AM | Banyan Hill Publishing (Ad)Truist Financial Keeps Their Hold Rating on Arcellx Inc (ACLX)April 10, 2026 | theglobeandmail.comAssessing Arcellx (ACLX) Valuation After Strong Multi‑Year Share Price GainsApril 8, 2026 | finance.yahoo.comAssessing Arcellx (ACLX) Valuation After Strong Multi Period Share Price MomentumMarch 25, 2026 | finance.yahoo.comArcellx Inc.March 24, 2026 | barrons.comHalper Sadeh LLC is Investigating Whether KW, ACLX are Obtaining Fair Deals for their ShareholdersMarch 19, 2026 | globenewswire.comSee More Headlines ACLX Stock Analysis - Frequently Asked Questions How were Arcellx's earnings last quarter? Arcellx, Inc. (NASDAQ:ACLX) announced its quarterly earnings results on Thursday, February, 26th. The company reported ($1.01) earnings per share for the quarter, meeting analysts' consensus estimates of ($1.01). The firm had revenue of $1.65 million for the quarter, compared to analysts' expectations of $13.40 million. Arcellx had a negative net margin of 1,027.26% and a negative trailing twelve-month return on equity of 55.42%. When did Arcellx IPO? Arcellx (ACLX) raised $132 million in an initial public offering (IPO) on Friday, February 4th 2022. The company issued 8,250,000 shares at $15.00-$17.00 per share. What other stocks do shareholders of Arcellx own? Based on aggregate information from My MarketBeat watchlists, some other companies that Arcellx investors own include Humana (HUM), NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), American Water Works (AWK), Arista Networks (ANET) and e.l.f. Beauty (ELF). Company Calendar Last Earnings2/26/2026Today7/20/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ACLX CIK1786205 Webarcellx.com Phone240-327-0603FaxN/AEmployees80Year Founded2015Price Target and Rating Average Price Target for Arcellx$111.87 High Price Target$133.00 Low Price Target$82.00 Potential Upside/Downside-2.8%Consensus RatingHold Rating Score (0-4)2.11 Research Coverage19 Analysts Profitability EPS (Trailing Twelve Months)($4.07) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$228.93 million Net Margins-1,027.26% Pretax Margin-1,026.94% Return on Equity-55.42% Return on Assets-36.24% Debt Debt-to-Equity RatioN/A Current Ratio4.44 Quick Ratio4.44 Sales & Book Value Annual Sales$22.29 million Price / Sales301.95 Cash FlowN/A Price / Cash FlowN/A Book Value$6.96 per share Price / Book16.53Miscellaneous Outstanding Shares58,480,000Free Float53,597,000Market Cap$6.73 billion OptionableOptionable Beta0.25 Social Links 7 Stocks to Buy And Hold ForeverClick the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report This page (NASDAQ:ACLX) was last updated on 7/20/2026 by MarketBeat.com Staff. From Our PartnersSMX: From Under-the-Radar to Must-Watch!SMX (Security Matters) PLC is building Digital Material Passport technology that embeds molecular-level marker...Smallcaps Daily | SponsoredBuy this stock tomorrowMarc Chaikin, founder of Chaikin Analytics, is flagging a little-known company that just secured a partnership...Chaikin Analytics | SponsoredMan who Predicted Trump 2016 Win: “Prepare for Mid-Term Meltdown”In 2016, major election models gave Hillary Clinton a 99% chance of winning - but former CIA and Pentagon advi...Paradigm Press | SponsoredAmerican’s Biggest Threat Is HereThis feels like one of those ''where were you when Kennedy was shot'' moments. It felt like a moment in time, ...Goldco Direct, LLC | SponsoredDo this before December or regret itPorter Stansberry believes President Trump will use the December G20 Summit in Miami to unveil a radical monet...Porter & Company | SponsoredYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...Profits Run | SponsoredIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...Banyan Hill Publishing | Sponsored27 insiders just called an emergency meetingA staggering $122 million traded on Polymarket and another $64 million on Kalshi on whether America would win ...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Arcellx, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Arcellx With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
